A study on Allergy Therapeutics' new hay fever treatment failed to find a recommended dose for a late-stage trial, a setback that will postpone the drug's U.S. launch by a year, according to Reuters.
The Britain-based drug developer originally expected to start a Phase 3 trial later this year and bring the drug to the market in 2020.
Now, the company must complete a new dose-ranging study, planned for 2017, before advancing to a Phase 3 trial.
Allergy Therapeutics, which specializes in allergy vaccines, will meet with the Food and Drug Administration later this year to discuss the drug.
This is the second allergy drug study to recently run into complications — Chicago-based Circassia Pharamceuticals' cat allergy treatment failed in a late-stage trial two weeks ago.
More articles on supply chain:
Leukocyte reduction devices recalled for faulty filters
How Britain's exit from the EU will affect the drug market
Natco Pharma earns FDA approval for ulcer drug